231 Safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of people with cystic fibrosis with the 3849 +10 kb C- >T mutation to support Phase 1/2a clinical study

DOI: 10.1016/s1569-1993(23)01161-x Publication Date: 2023-10-18T06:00:09Z